Overview

A Ph 1 Study of Epanova® in Healthy Chineses

Status:
Completed
Trial end date:
2018-06-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety, tolerability, and PK of single and multiple doses of Epanova in healthy male and female Chinese subjects and to allow comparison of these parameters with the Western population studied to date.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca